Abstract:BackgroundPortal hypertension is a key complication of portal hypertension, which is responsible for the development of varices, ascites, bleeding, and hepatic encephalopathy, which, in turn, cause a high mortality and requirement for liver transplantation.AimThis review deals with the present day state-of-the-art preventative treatments of portal hypertension in cirrhosis according to disease stage. Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension.ResultsThe aim of treatment in compensated cirrhosis is preventing clinical decompensation, the more frequent event being ascites, followed by variceal bleeding and hepatic encephalopathy. Complications are mainly driven by an increase of hepatic vein pressure gradient (HVPG) to values ≥10 mmHg (defining the presence of Clinically Significant Portal Hypertension, CSPH). Before CSPH, the treatment is limited to etiologic treatment of cirrhosis and healthy life style (abstain from alcohol, avoid/correct obesity…). When CSPH is present, association of a non-selective beta-blocker (NSBB), including carvedilol should be considered. NSBBs are mandatory if moderate/large varices are present. Patients should also enter a screening program for hepatocellular carcinoma. In decompensated patients, the goal is to prevent further bleeding if the only manifestation of decompensation was a bleeding episode, but to prevent liver transplantation and death in the common scenario where patients have manifested first non-bleeding complications. Treatment is based on the same principles (healthy life style..) associated with administration of NSBBs in combination if possible with endoscopic band ligation if there has been variceal bleeding, and complemented with simvastatin administration (20-40 mg per day in Child–Pugh A/B, 10–20 mg in Child C). Recurrence shall be treated with TIPS. TIPS might be indicated earlier in patients with: 1) Difficult/refractory ascites, who are not the best candidates for NSBBs, 2) patients having bleed under NSBBs or showing no HVPG response (decrease in HVPG of at least 20% of baseline or to values equal or below 12 mmHg). Decompensated patients shall all be considered as potential candidates for liver transplantation.ConclusionTreatment of portal hypertension has markedly improved in recent years. The present day therapy is based on accurate risk stratification according to disease stage.

Current Status of the Clinical Management of Non-Cirrhotic Portal Hypertension

Treatment Options for Portal Hypertension in the Era of Liver Transplantation

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Non-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management

Idiopathic Noncirrhotic Portal Hypertension: An Appraisal

Intrinsic Causes of Nonfibrotic Portal Hypertension—A Clinicopathologic Review of 56 Patients

Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives

Porto-Sinusoidal Vascular Disease: A New Nomenclature Different from Idiopathic Non-Cirrhotic Portal Hypertension

Application of liver biopsy in etiological diagnosis of unexplained portal hypertension: Porto-sinusoidal vascular disease should not be ignored

Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges

Etiology and management of portal vein thrombosis：recent progress in research

[Exploring Scientific Research with the Participation of Multidisciplinary Team in the Clinical Management of Portal Hypertension].

Bibliometric-analysis visualization and review of non-invasive methods for monitoring and managing the portal hypertension

Current and investigational drugs in early clinical development for portal hypertension

S4278 Questioning Assumptions: Non-Cirrhotic Portal Hypertension

Practicing clinical research and multidisciplinary team management of portal hypertension

[Clinical Characteristics of Hepatic Sinusoidal Obstruction Syndrome: Analysis of 8 Cases].

Regression of portal hypertension: underlying mechanisms and therapeutic strategies

Portal Hypertension in Non-alcoholic Fatty Liver Disease in the Era of Non-invasive Assessment

Subharmonic Aided Pressure Estimation in Portal Hypertension: A Noninvasive Ultrasound‐based Technique to Assess Portal Pressure Gradient

Clinical analysis of surgical treatment of portal hypertension.